Guidelines For Clinical Practice
Copyright ©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Sep 21, 2012; 18(35): 4823-4854
Published online Sep 21, 2012. doi: 10.3748/wjg.v18.i35.4823
Table 31 Meta-analysis efficacy of 5-aminosalicylic acid/sulfasalazine to induce remission or to prevent relapse in Crohn's disease
Induce remission (RR of not being in remission) on active therapyPrevent relapse (RR of relapse)
CDSASP (only 2 RCTs) 0.83 (95%CI: 0.69-1.00; trend)SASP/5-ASA, ITT analysis, no benefit
5-ASA 0.91 (95%CI: 0.77-1.06; not significant)5-ASA, PP analysis: RR = 0.79 (95%CI: 0.66-0.95; NNT = 13 to prevent relapse)
UC0.79 (95%CI: 0.73-0.85; NNT = 6)0.65 (95%CI: 0.55-0.76; NNT = 4 to prevent relapse)